BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Prince HM, Duvic M, Martin A, Sterry W, Assaf C, Straus DJ. Incidence of spontaneous remission in patients with CD25-positive mycosis fungoides/Sézary syndrome receiving placebo. J Am Acad Dermatol. 2012;67:867-875. [PMID: 22285675 DOI: 10.1016/j.jaad.2011.12.027] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 . Mycosis fungoides. Skin Lymphoma. Wiley; 2020. pp. 23-112. [DOI: 10.1002/9781119485933.ch3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Prince HM, Newland KM. Denileukin diftitox for the treatment of cutaneous T-cell lymphoma. Expert Opinion on Orphan Drugs 2014;2:625-34. [DOI: 10.1517/21678707.2014.912580] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
3 Prince HM, Martin AG, Olsen EA, Fivenson DP, Duvic M. Denileukin diftitox for the treatment of CD25 low-expression mycosis fungoides and Sézary syndrome. Leuk Lymphoma 2013;54:69-75. [PMID: 22738414 DOI: 10.3109/10428194.2012.706286] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
4 Tomasini C, Michelerio A, Quaglino P. Spiky/keratosis-pilaris-like early follicular mycosis fungoides: A clinicopathologic study of 20 cases with extended follow-up. J Cutan Pathol 2021;48:1124-32. [PMID: 33675561 DOI: 10.1111/cup.14002] [Reference Citation Analysis]
5 Spalletta G, Long JD, Robinson RG, Trequattrini A, Pizzoli S, Caltagirone C, Orfei MD. Longitudinal Neuropsychiatric Predictors of Death in Alzheimer's Disease. J Alzheimers Dis 2015;48:627-36. [PMID: 26402103 DOI: 10.3233/JAD-150391] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 6.4] [Reference Citation Analysis]
6 Duvic M, Geskin L, Prince HM. Duration of Response in Cutaneous T-Cell Lymphoma Patients Treated With Denileukin Diftitox: Results From 3 Phase III Studies. Clinical Lymphoma Myeloma and Leukemia 2013;13:377-84. [DOI: 10.1016/j.clml.2013.02.020] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]